Nothing
Code
cat(export_as_txt(res, lpp = 100, cpp = 200))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Total number of patients with at least one AE 13 (86.7%) 14 (93.3%) 15 (100%)
Total number of AEs 58 59 99
Total number of patients with at least one AE by worst grade
Grade 1 0 1 (6.7%) 1 (6.7%)
Grade 2 1 (6.7%) 1 (6.7%) 1 (6.7%)
Grade 3 1 (6.7%) 2 (13.3%) 1 (6.7%)
Grade 4 3 (20.0%) 2 (13.3%) 2 (13.3%)
Grade 5 (fatal outcome) 8 (53.3%) 8 (53.3%) 10 (66.7%)
Total number of patients with study drug withdrawn due to AE 0 0 0
Total number of patients with dose modified/interrupted due to AE 0 0 0
Total number of patients with treatment received for AE 0 0 0
Total number of patients with all non-fatal AEs resolved 9 (60.0%) 10 (66.7%) 12 (80.0%)
Total number of patients with at least one unresolved or ongoing non-fatal AE 10 (66.7%) 9 (60.0%) 14 (93.3%)
Total number of patients with at least one serious AE 0 0 0
Total number of patients with at least one related AE 11 (73.3%) 10 (66.7%) 13 (86.7%)
Code
cat(export_as_txt(res, lpp = 100, cpp = 200))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Total number of patients with at least one AE 13 (86.7%) 14 (93.3%) 15 (100%)
Total number of AEs 58 59 99
Total number of patients with at least one AE by worst grade
Grade 1 0 1 (6.7%) 1 (6.7%)
Grade 2 1 (6.7%) 1 (6.7%) 1 (6.7%)
Grade 3 1 (6.7%) 2 (13.3%) 1 (6.7%)
Grade 4 3 (20.0%) 2 (13.3%) 2 (13.3%)
Grade 5 (fatal outcome) 8 (53.3%) 8 (53.3%) 10 (66.7%)
Total number of patients with all non-fatal AEs resolved 9 (60.0%) 10 (66.7%) 12 (80.0%)
Total number of patients with at least one unresolved or ongoing non-fatal AE 10 (66.7%) 9 (60.0%) 14 (93.3%)
Total number of patients with at least one related AE 11 (73.3%) 10 (66.7%) 13 (86.7%)
Code
cat(export_as_txt(res, lpp = 100, cpp = 200))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Total number of patients with at least one AE 13 (86.7%) 14 (93.3%) 15 (100%)
Total number of AEs 58 59 99
Total number of patients with at least one AE by worst grade
Grade 1 0 1 (6.7%) 1 (6.7%)
Grade 2 1 (6.7%) 1 (6.7%) 1 (6.7%)
Grade 3 1 (6.7%) 2 (13.3%) 1 (6.7%)
Grade 4 3 (20.0%) 2 (13.3%) 2 (13.3%)
Grade 5 (fatal outcome) 8 (53.3%) 8 (53.3%) 10 (66.7%)
Total number of patients with study drug withdrawn due to AE 1 (6.7%) 3 (20.0%) 3 (20.0%)
Total number of patients with dose modified/interrupted due to AE 6 (40.0%) 9 (60.0%) 11 (73.3%)
Total number of patients with treatment received for AE 10 (66.7%) 10 (66.7%) 14 (93.3%)
Total number of patients with all non-fatal AEs resolved 9 (60.0%) 10 (66.7%) 12 (80.0%)
Total number of patients with at least one unresolved or ongoing non-fatal AE 10 (66.7%) 9 (60.0%) 14 (93.3%)
Total number of patients with at least one serious AE 12 (80.0%) 12 (80.0%) 11 (73.3%)
Total number of patients with at least one related AE 11 (73.3%) 10 (66.7%) 13 (86.7%)
ALL
argumentCode
cat(export_as_txt(res, lpp = 100, cpp = 200))
Output
A: Drug X B: Placebo C: Combination
(N=15) (N=15) (N=15)
———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Total number of patients with at least one AE 13 (86.7%) 14 (93.3%) 15 (100%)
Total number of AEs 58 59 99
Total number of patients with at least one AE by worst grade
Grade 1 0 1 (6.7%) 1 (6.7%)
Grade 2 1 (6.7%) 1 (6.7%) 1 (6.7%)
Grade 3 1 (6.7%) 2 (13.3%) 1 (6.7%)
Grade 4 3 (20.0%) 2 (13.3%) 2 (13.3%)
Grade 5 (fatal outcome) 8 (53.3%) 8 (53.3%) 10 (66.7%)
Total number of patients with study drug withdrawn due to AE 2 (13.3%) 3 (20.0%) 3 (20.0%)
Total number of patients with dose modified/interrupted due to AE 6 (40.0%) 9 (60.0%) 11 (73.3%)
Total number of patients with treatment received for AE 10 (66.7%) 10 (66.7%) 14 (93.3%)
Total number of patients with all non-fatal AEs resolved 9 (60.0%) 10 (66.7%) 12 (80.0%)
No. of patients with study drug withdrawn due to resolved AE 1 (6.7%) 2 (13.3%) 2 (13.3%)
No. of patients with dose modified/interrupted due to resolved AE 3 (20.0%) 6 (40.0%) 7 (46.7%)
No. of patients with treatment received for resolved AE 7 (46.7%) 5 (33.3%) 7 (46.7%)
Total number of patients with at least one unresolved or ongoing non-fatal AE 10 (66.7%) 9 (60.0%) 14 (93.3%)
No. of patients with study drug withdrawn due to unresolved or ongoing AE 1 (6.7%) 1 (6.7%) 1 (6.7%)
No. of patients with dose modified/interrupted due to unresolved or ongoing AE 3 (20.0%) 3 (20.0%) 7 (46.7%)
No. of patients with treatment received for unresolved/ongoing AE 6 (40.0%) 6 (40.0%) 11 (73.3%)
Total number of patients with at least one serious AE 12 (80.0%) 12 (80.0%) 11 (73.3%)
No. of patients with study drug withdrawn due to serious AE 0 0 2 (13.3%)
No. of patients with dose modified/interrupted due to serious AE 4 (26.7%) 3 (20.0%) 4 (26.7%)
No. of patients with treatment received for serious AE 8 (53.3%) 9 (60.0%) 8 (53.3%)
Total number of patients with at least one related AE 11 (73.3%) 10 (66.7%) 13 (86.7%)
No. of patients with study drug withdrawn due to related AE 0 3 (20.0%) 0
No. of patients with dose modified/interrupted due to related AE 1 (6.7%) 4 (26.7%) 9 (60.0%)
No. of patients with treatment received for related AE 5 (33.3%) 6 (40.0%) 9 (60.0%)
No. of patients with serious, related AE 8 (53.3%) 8 (53.3%) 10 (66.7%)
Any scripts or data that you put into this service are public.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.